FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.895,43 -1.352,04 (-2,24%)
Heart Test Laboratories, Inc. (HSCS)
Dopo ore:
| Chiusura precedente | 0,0999 |
| Aperto | 0,0969 |
| Denaro | 0,0000 x 0 |
| Lettera | 1,2500 x 100 |
| Min-Max giorno | 0,0936 - 0,1016 |
| Intervallo di 52 settimane | 0,0910 - 1,3200 |
| Volume | |
| Media Volume | 1.906.242 |
| Capitalizzazione | 6,386M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3500 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 0,68 |
GlobeNewswireHeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
Patents Cover MyoVista® Wavelet Technology Utilizing AI for Early Detection of Heart DiseaseSouthlake, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been issued a notice of patent allowance from the Brazilian Patent and Trademark Offic
- GlobeNewswire
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
Southlake, TX, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Company CEO, Andrew Simpson, will present at Maxim Group’s Virtual Tech Conference Series: Emerging Growth in A.I on Wednesday, September 27th, 2023, at 10:30 a.m.
- GlobeNewswire
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
Southlake, TX, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced it has executed definitive agreements with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), in New York, NY, to commercialize electrocardiographic AI algorithms and assets, as w
